These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 25582139)
1. Elderly patients with squamous cell carcinoma of the head and neck and the benefit of multimodality therapy. Moye VA; Chandramouleeswaran S; Zhao N; Muss HB; Weissler MC; Hayes DN; Zevallos JP Oncologist; 2015 Feb; 20(2):159-65. PubMed ID: 25582139 [TBL] [Abstract][Full Text] [Related]
2. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Iyer NG; Tan DS; Tan VK; Wang W; Hwang J; Tan NC; Sivanandan R; Tan HK; Lim WT; Ang MK; Wee J; Soo KC; Tan EH Cancer; 2015 May; 121(10):1599-607. PubMed ID: 25639864 [TBL] [Abstract][Full Text] [Related]
3. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity]. Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261 [TBL] [Abstract][Full Text] [Related]
4. Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma. van den Broek GB; Rasch CR; Pameijer FA; Peter E; van den Brekel MW; Tan IB; Schornagel JH; de Bois JA; Zijp LJ; Balm AJ Cancer; 2004 Oct; 101(8):1809-17. PubMed ID: 15386309 [TBL] [Abstract][Full Text] [Related]
5. Distant metastases in head-and-neck squamous cell carcinoma treated with intensity-modulated radiotherapy. Yao M; Lu M; Savvides PS; Rezaee R; Zender CA; Lavertu P; Buatti JM; Machtay M Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):684-9. PubMed ID: 22169673 [TBL] [Abstract][Full Text] [Related]
6. A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck. Manyam BV; Garsa AA; Chin RI; Reddy CA; Gastman B; Thorstad W; Yom SS; Nussenbaum B; Wang SJ; Vidimos AT; Koyfman SA Cancer; 2017 Jun; 123(11):2054-2060. PubMed ID: 28171708 [TBL] [Abstract][Full Text] [Related]
7. Survival Patterns in Elderly Head and Neck Squamous Cell Carcinoma Patients Treated With Definitive Radiation Therapy. Sommers LW; Steenbakkers RJHM; Bijl HP; Vemer-van den Hoek JGM; Roodenburg JLN; Oosting SF; Halmos GB; de Rooij SE; Langendijk JA Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):793-801. PubMed ID: 28476434 [TBL] [Abstract][Full Text] [Related]
8. Effects of ERCC2 Lys751Gln (A35931C) and CCND1 (G870A) polymorphism on outcome of advanced-stage squamous cell carcinoma of the head and neck are treatment dependent. Zhong S; Nukui T; Buch S; Diergaarde B; Weissfeld LA; Grandis J; Romkes M; Weissfeld JL Cancer Epidemiol Biomarkers Prev; 2011 Nov; 20(11):2429-37. PubMed ID: 21890746 [TBL] [Abstract][Full Text] [Related]
9. Treatment of squamous cell carcinoma of external auditory canal: A tertiary cancer centre experience. Gandhi AK; Roy S; Biswas A; Raza MW; Saxena T; Bhasker S; Sharma A; Thakar A; Mohanti BK Auris Nasus Larynx; 2016 Feb; 43(1):45-9. PubMed ID: 26165629 [TBL] [Abstract][Full Text] [Related]
10. Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status. Lowe NM; Bernstein JM; Mais K; Garcez K; Lee LW; Sykes A; Thomson DJ; Homer JJ; West CM; Slevin NJ J Cancer Res Clin Oncol; 2018 Feb; 144(2):389-401. PubMed ID: 29222650 [TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of basaloid squamous cell carcinoma in head and neck cancer. Linton OR; Moore MG; Brigance JS; Gordon CA; Summerlin DJ; McDonald MW JAMA Otolaryngol Head Neck Surg; 2013 Dec; 139(12):1306-11. PubMed ID: 24158536 [TBL] [Abstract][Full Text] [Related]
12. Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base. Amini A; Jones BL; McDermott JD; Serracino HS; Jimeno A; Raben D; Ghosh D; Bowles DW; Karam SD Cancer; 2016 May; 122(10):1533-43. PubMed ID: 26969811 [TBL] [Abstract][Full Text] [Related]
13. Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community. Maguire PD; Meyerson MB; Neal CR; Hamann MS; Bost AL; Anagnost JW; Ungaro PC; Pollock HD; McMurray JE; Wilson EP; Kotwall CA Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):698-704. PubMed ID: 14967423 [TBL] [Abstract][Full Text] [Related]
14. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. Pfister DG; Su YB; Kraus DH; Wolden SL; Lis E; Aliff TB; Zahalsky AJ; Lake S; Needle MN; Shaha AR; Shah JP; Zelefsky MJ J Clin Oncol; 2006 Mar; 24(7):1072-8. PubMed ID: 16505426 [TBL] [Abstract][Full Text] [Related]
15. High-dose cisplatin concurrent to conventionally delivered radiotherapy is associated with unacceptable toxicity in unresectable, non-metastatic stage IV head and neck squamous cell carcinoma. de Castro G; Snitcovsky IM; Gebrim EM; Leitão GM; Nadalin W; Ferraz AR; Federico MH Eur Arch Otorhinolaryngol; 2007 Dec; 264(12):1475-82. PubMed ID: 17643256 [TBL] [Abstract][Full Text] [Related]
16. Inferior outcomes in immunosuppressed patients with high-risk cutaneous squamous cell carcinoma of the head and neck treated with surgery and radiation therapy. Manyam BV; Gastman B; Zhang AY; Reddy CA; Burkey BB; Scharpf J; Alam DS; Fritz MA; Vidimos AT; Koyfman SA J Am Acad Dermatol; 2015 Aug; 73(2):221-7. PubMed ID: 26028524 [TBL] [Abstract][Full Text] [Related]
17. Elderly Patients with Advanced Head and Neck Carcinoma: Does Aggressive Treatment Result in Better Outcomes? Jang IJH; Skanthakumar T; Tan HK; Tan NC; Soo KC; Iyer NG Otolaryngol Head Neck Surg; 2019 Apr; 160(4):642-650. PubMed ID: 30558490 [TBL] [Abstract][Full Text] [Related]
18. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418 [TBL] [Abstract][Full Text] [Related]
19. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. Bernier J; Domenge C; Ozsahin M; Matuszewska K; Lefèbvre JL; Greiner RH; Giralt J; Maingon P; Rolland F; Bolla M; Cognetti F; Bourhis J; Kirkpatrick A; van Glabbeke M; N Engl J Med; 2004 May; 350(19):1945-52. PubMed ID: 15128894 [TBL] [Abstract][Full Text] [Related]
20. Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer. Kovács AF; Mose S; Böttcher HD; Bitter K Strahlenther Onkol; 2005 Jan; 181(1):26-34. PubMed ID: 15660190 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]